Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

51.7K
Overview
51.7K
What are Viruses?00:50

What are Viruses?

128.1K
Overview
128.1K
Cancer Vaccines01:30

Cancer Vaccines

1.0K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.0K
Tumor Progression02:07

Tumor Progression

7.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.4K
Electrical Current01:10

Electrical Current

7.2K
Electrical current is defined as the rate at which charge flows. When there is a large current present, such as that used to run a refrigerator, a large amount of charge moves through the wire in a small amount of time. If the current is small, such as that used to operate a handheld calculator, a small amount of charge moves through the circuit over a long period of time. The SI unit for current is the ampere (A), named for the French physicist André-Marie Ampère (1775–1836).
7.2K
Current Density01:21

Current Density

5.1K
The total amount of current flowing through one unit value of a cross-sectional area is referred to as current density. If the current flow is uniform, the amount of current flowing through a conductor is the same at all points along the conductor, even if the conductor area varies. The current density consists of the local magnitude and direction of the charge flow, which varies from point to point. Current density is measured in amperes per meter square, and direction is defined as the net...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Single-Dose Bundibugyo Virus Vaccine Protects Macaques Within 3 Days.

bioRxiv : the preprint server for biology·2026
Same author

Genome sequence of a historical vesicular stomatitis New Jersey virus isolate collected in 1965 from a naturally infected cow in El Salvador.

Microbiology resource announcements·2026
Same author

Comparison of Ebola virus infection routes and resulting disease in animal models.

Journal of virology·2026
Same author

Griffithsin-mediated inhibition of cellular entry of hemorrhagic fever viruses and insights into its mechanisms.

Journal of virology·2026
Same author

Transcriptional signatures of rapid protection from Sudan virus infection by a single dose of a vesicular stomatitis virus-based vaccine.

PLoS pathogens·2026
Same author

Glycoprotein-specific transcriptional response contributes to differential vaccine protection against lethal Ebola virus infection.

Vaccine·2026

Related Experiment Video

Updated: Jan 31, 2026

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

37.0K

Current Ebola Virus Vaccine Progress.

Andrea Marzi1, Chad E Mire2

  • 1Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MO, USA.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|January 4, 2019
PubMed
Summary

Despite significant progress in Ebola virus vaccine development, with over 12 candidates and one in Phase III trials, key questions about immunity duration and optimal vaccination strategies remain. Further research is crucial for effective Ebola virus control.

More Related Videos

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.8K
In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
09:04

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Published on: May 11, 2020

13.3K

Related Experiment Videos

Last Updated: Jan 31, 2026

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

37.0K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.8K
In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
09:04

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Published on: May 11, 2020

13.3K

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Ebola virus disease (EVD) remains a significant public health threat.
  • Over 40 years since its discovery, effective vaccines are still under development.
  • Past decades have seen numerous vaccine candidates emerge.

Purpose of the Study:

  • To review the progress of anti-Ebola virus vaccine candidates.
  • To identify remaining challenges in vaccine development and deployment.
  • To highlight critical areas for future research in EVD prevention.

Main Methods:

  • Review of clinical trial data for Ebola virus vaccine candidates.
  • Analysis of vaccine development pipelines.
  • Identification of knowledge gaps in vaccine efficacy and strategy.

Main Results:

  • Over 12 Ebola virus vaccine candidates have been developed.
  • Four candidates have reached Phase II clinical trials.
  • One candidate has successfully completed Phase III clinical trials.

Conclusions:

  • Remarkable progress has been made toward an approved Ebola virus vaccine.
  • Unanswered questions persist regarding vaccine-induced protective immunity and its duration.
  • Optimal vaccination strategies for at-risk populations require further investigation.